Oncology Drugs

A new interactive lab and large-scale survey aim to combat pervasive gum disease. How does this data-driven approach fit into Hong Kong's public health landscape?

A new ultra-short-acting drug for cardiac emergencies is now in US hospitals, offering doctors faster control and broader use across all age groups.

With a massive Series A, Coultreon Biopharma is advancing a novel SIK3 inhibitor spun out of Galapagos to rival injectable blockbusters for autoimmune disease.

A UK firm's breakthrough blood test for early breast cancer detection joins a prestigious EU network, aiming to personalize treatment and redefine diagnostics.

The Health Research Foundation opens nominations for its equity award, spotlighting researchers who are closing critical health gaps for diverse communities.

A new financial deal shines a light on Modeyso, a breakthrough therapy for a rare pediatric brain cancer, linking Wall Street to life-saving innovation.

A novel, minimally invasive nerve ablation technology shows long-term promise for relieving severe pancreatic cancer pain, a major unmet medical need.

With the hire of world-renowned surgeon Dr. Nelson Oyesiku, Piedmont Healthcare signals its ambition to become a top destination for neurological care in the Southeast.

A $500K grant accelerates a novel therapy that dismantles tumor defenses, offering new hope for patients with hard-to-treat gastroesophageal cancers.

New data shows Synthekine's STK-012 overcomes resistance to standard therapy, offering hope for patients with immune-cold non-small cell lung cancer.

A novel drug that targets the cellular environment of the MYC cancer protein, not the protein itself, shows major promise in preclinical studies.

Dizal to unveil late-breaking ZEGFROVY data for NSCLC, plus new findings for drugs tackling resistance and boosting immunotherapy at ASCO 2026.

Harrington Discovery Institute opens its 2027 award call, offering millions in funding and expert support to turn academic research into life-saving medicines.

With a $30M+ boost and a public market debut, Ionetix aims to scale its cyclotron tech for cancer therapy, diagnostics, and future energy solutions.

Following a breakthrough in chondrosarcoma, Inhibrx Biosciences is set to reveal pivotal data for its drug ozekibart in the vast colorectal cancer market.

Freshly spun-off from AnaptysBio, First Tracks Biotherapeutics hits the market with a strong cash position and a pipeline aimed at celiac disease and RA.

PeptiDream and Asahi Kasei's novel drug candidate, AK1940, begins Phase 1 trials, aiming for a safer, more targeted approach to treating autoimmune diseases.

With Cigna's backing, Accord's IMULDOSA is set to challenge a blockbuster drug, promising significant savings for patients and the healthcare system.

A new bispecific antibody, EPI-326, enters human trials, hoping its unique tissue-selective degradation can defeat EGFR-driven cancers where others fail.

New preclinical data reveals a novel drug, rinzimetostat, may overcome treatment resistance in prostate cancer by targeting a unique molecular switch.